RecruitingNCT06993220

Evaluating Residual Congestion at Discharge in Acute Heart Failure Patients

Multiparametric Assessment of Residual Congestion at Discharge in Patients With Acute Heart Failure


Sponsor

Consorci Sanitari Integral

Enrollment

500 participants

Start Date

Jan 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Treatment of congestion is one of the main goals in patients hospitalized for acute heart failure. Nevertheless, current evidence shows that decongestion is often not achieved and that residual congestion at discharge is strongly associated with poor outcomes. While this association has been demonstrated, previous studies have primarily focused on single parameters of congestion (physical examination, biomarkers, or imaging features). The aim of the study is to assess residual congestion at discharge using a multiparametric approach and to compare the prognostic value of each evaluation strategy. Additionally, the analysis will be supported by artificial intelligence to develop a multiparametric prognostic algorithm that can provide an improved predictive model compared to standard statistical approaches.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Age ≥ 18 years.
  • Patients hospitalized for new onset heart failure or worsening heart failure defined by:
  • Symptoms classified as New York Heart Association class III or IV.
  • Clinical or instrumental signs of volume overload (e.g., dyspnea with evidence of pulmonary congestion on X-rays or lung ultrasound, pitting edema, and jugular venous distension).
  • Elevated NT-proBNP levels within the first 24 hours of admission (cutoff values: 450 ng/L for patients \< 50 years; \>900 ng/L for patients aged 50-75 years; \>1800 ng/L for patients \>75 years).
  • Ability to provide informed consent.

Exclusion Criteria9

  • Known diagnosis of septicemia.
  • Glomerular filtration rate \< 15 ml/min.
  • Life expectancy \< 6 months.
  • Active myocarditis.
  • Heart transplant recipients.
  • Patients with ventricular assist devices.
  • Congenital heart diseases.
  • Moderate-to-severe liver disease (Child-Pugh B-C).
  • Patients that will not be followed up by the Heart Failure Unit.

Interventions

DIAGNOSTIC_TESTEvaluation of residual congestion at discharge

Evaluation of residual congestion at discharge will be made using: * Clinical variables: composite congestion score calculated by summing the individual scores for orthopnoea, jugular venous distension and pedal oedema; * Imaging variables: non-invasive left ventricular filling pressure, number of LUS B lines and the presence of pleural effusion, Venous Excess UltraSound (VExUS) score; * Laboratory variables: hemoglobin and hematocrit, NT-proBNP, CA-125, ST2, troponin T, creatinine, AST, ALT, Na, K, urea, bilirubin, C-reactive protein.


Locations(1)

Complex Hospitalari Universitari Moisès Broggi

Sant Joan Despí, Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06993220


Related Trials